Medical Device News Magazine

VERITAS Vision System Is Introduced by Johnson & Johnson

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Johnson & Johnson Vision,* a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, today announced the global availability of the VERITAS Vision System, a next-generation phacoemulsification (phaco) system designed to address three critical areas: patient safety, surgeon efficiency and comfort.

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting.

Approximately 50% of people over the age of 75 have cataracts1 and cataract surgery is one of the most common outpatient procedures performed today with a success rate of approximately 98%.2 Phacoemulsification is the most common cataract surgery technique3 and allows surgeons to effectively emulsify and efficiently remove the eye’s internal lens when it has become cloudy from cataracts. It is a delicate procedure that requires significant effort and control, which can be taxing on the surgeon. Equipment that surgeons can rely on through surgery is critical to optimizing the circumstances for surgical success.

“In my experience, the advancements in fluidics management and usability of the VERITAS Vision System have made a marked improvement in safety and stability of the phaco procedure,” said Jason Jones, M.D.§, Jones Eye Clinic, Sioux City, Iowa. “I’ve found I can glide through any lens density with less surge, and the level of chamber stability I’ve experienced with VERITAS gives me more confidence to take advantage of Venturi mode, the more powerful phaco setting.”

“Surgeon-centered equipment design is vital for an exacting and taxing procedure like phacoemulsification,” said Dr. Marco Tavolato, Head of Eye Centre, Chioggia Hospital, Italy.** “The advancements Johnson & Johnson Vision has made in phaco technology reinforce that the company is listening and tailoring innovations to surgeons’ needs. From safety features like Hybrid Fluidics Technology, to the nuances of a more ergonomic design for comfort and control, these advancements have made a measurable difference in my surgical day, and ease even the most challenging phaco cases.”

The VERITAS Vision System features several innovations to provide a better surgical experience, including:

  • Less surge, more stability
    • Hybrid Fluidics Technology minimizes post-occlusion surge to protect intraocular structures and provide exceptional chamber stability.††,‡‡
    • Intelligent Occlusion Sensing Technologies automatically respond to occlusions to preserve a calm, stable chamber even in dense cataract cases.§§
  • Exceptional phacoemulsification efficiency
    • Built using the company’s leading WHITESTAR technology combined with elliptical tip movement for ultra-smooth cutting, even in dense or advanced cataracts, providing an efficient lens extraction that uses less energy.***
    • Dual Pump System allows access to both Peristaltic and Venturi pumps with on-demand transition between the two at every step, allowing surgeons to adapt to clinical needs.‡‡
  • Surgeon-centered ergonomics for maneuverability and comfort
    • Between 52-80% of ophthalmologists report back and neck pain because of their work4 and 43% take breaks during surgery due to pain.5
    • An ergonomically designed foot pedal provides total control and a more comfortable experience.†††

“On top of providing a safe and stable procedure for cataract patients, we wanted to also offer a more efficient and comfortable phacoemulsification experience for surgeons, especially knowing most will perform multiple cataract surgeries every day,” said Warren Foust, Worldwide President, Surgical at Johnson & Johnson Vision.‡‡‡ “Our VERITAS Vision System delivers high-performing, reliable tools for a smooth, effective cataract surgery for patients while also prioritizing surgeon well-being.”

The VERITAS Vision System is the latest addition to the company’s full suite of industry leading products for the treatment of cataracts. The global launch comes as the Johnson & Johnson Vision celebrates two 20-year anniversaries: WHITESTAR micropulse technology, a major advancement in phacoemulsification efficiency10, the TECNIS Family of IOLs, which established the company’s legacy of innovation in cataract treatment.

The VERITAS Vision System is now available for ophthalmologists across the United States, Europe and select markets in the Asia Pacific region to use in their treatment of cataracts and will be available later this year in Chile and Brazil.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”